(Q38554910)

4 September 2017

1 reference

title

Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions (English)

1 reference

4 September 2017

0 references

1 reference

2

1 reference

4 September 2017

Simon Lovestone

3

0 references

Bruno Vellas

series ordinal

5

object named as

Bruno Vellas

1 reference

4 September 2017

4

Paul S Aisen

1 reference

4 September 2017

Sandrine Andrieu

1

1 reference

4 September 2017

23 July 2015

1 reference

4 September 2017

1 reference

4 September 2017

14

1 reference

4 September 2017

9

1 reference

4 September 2017

926-944

1 reference

The worldwide economic impact of dementia 2010.

4 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Is dementia incidence declining?: Trends in dementia incidence since 1990 in the Rotterdam Study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

The coming acceleration of global population ageing

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

The global prevalence of dementia: a systematic review and metaanalysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Forecasting the global burden of Alzheimer’s disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Potential for primary prevention of Alzheimer's disease: an analysis of population-based data

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Dementia prevention: methodological explanations for inconsistent results

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

National Institutes of Health State-of-the-Science Conference statement: preventing alzheimer disease and cognitive decline

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Designing prevention programmes to reduce incidence of dementia: prospective cohort study of modifiable risk factors.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

The projected effect of risk factor reduction on Alzheimer's disease prevalence

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

1 reference

7 January 2021

Primary prevention and delay of onset of AD/dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

A conceptual framework and ethics analysis for prevention trials of Alzheimer Disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

The A4 study: stopping AD before symptoms begin?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Testing the right target and right drug at the right stage

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Brain amyloid imaging--FDA approval of florbetapir F18 injection.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

1 reference

7 January 2021

Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Plasma Abeta, homocysteine, and cognition: the Vitamin Intervention for Stroke Prevention (VISP) trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Effects of cognitive training interventions with older adults: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Vitamin E and donepezil for the treatment of mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Vitamins B(12), B(6), and folic acid for cognition in older men.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Ginkgo biloba for prevention of dementia: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

A randomized double-blind trial of the effects of hormone therapy on delayed verbal recall in older women

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Safety and efficacy of galantamine in subjects with mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

A controlled trial of homocysteine lowering and cognitive performance

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Effect of oral vitamin B-12 with or without folic acid on cognitive function in older people with mild vitamin B-12 deficiency: a randomized, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Chronic endurance exercise training prevents aging-related cognitive decline in healthy older adults: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Effect of fish oil on cognitive performance in older subjects: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Effect of 2-y n-3 long-chain polyunsaturated fatty acid supplementation on cognitive function in older people: a randomized, double-blind, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

A cognitive training program based on principles of brain plasticity: results from the Improvement in Memory with Plasticity-based Adaptive Cognitive Training (IMPACT) study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Complex mental and physical activity in older women and cognitive performance: a 6-month randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

A randomized controlled trial of dietetic interventions to prevent cognitive decline in old age hostel residents.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Cocoa flavanol consumption improves cognitive function, blood pressure control, and metabolic profile in elderly subjects: the Cocoa, Cognition, and Aging (CoCoA) Study--a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Benefits in cognitive function, blood pressure, and insulin resistance through cocoa flavanol consumption in elderly subjects with mild cognitive impairment: the Cocoa, Cognition, and Aging (CoCoA) study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Resistance training and executive functions: a 12-month randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Multifactorial vascular risk factor intervention to prevent cognitive impairment after stroke and TIA: a 12-month randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

The PACE study: a randomized clinical trial of cognitive activity strategy training for older people with mild cognitive impairment.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Exergaming and older adult cognition: a cluster randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

The Mental Activity and eXercise (MAX) trial: a randomized controlled trial to enhance cognitive function in older adults

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Effects of a multidomain lifestyle modification on cognitive function in older adults: an eighteen-month community-based cluster randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Randomized controlled trial of a healthy brain ageing cognitive training program: effects on memory, mood, and sleep.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

A randomized controlled trial of cognitive training using a visual speed of processing intervention in middle aged and older adults.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Effectiveness of cognitive training for Chinese elderly in Hong Kong

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

A randomized controlled trial of multicomponent exercise in older adults with mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: the TRIMCI study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Alzheimer's disease: clinical trials and drug development

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Pathways to Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Disease-modifying therapies for Alzheimer disease: challenges to early intervention

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Alzheimer’s drugs take a new tack

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

The older people, omega-3, and cognitive health (EPOCH) trial design and methodology: a randomised, double-blind, controlled trial investigating the effect of long-chain omega-3 fatty acids on cognitive ageing and wellbeing in cognitively healthy ol

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Prevention of dementia by intensive vascular care (PreDIVA): a cluster-randomized trial in progress

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Rationale and design of the Kronos Early Estrogen Prevention Study (KEEPS) and the KEEPS Cognitive and Affective sub study (KEEPS Cog)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

The LIFE Cognition Study: design and baseline characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Protocol for a randomized controlled trial evaluating the effect of physical activity on delaying the progression of white matter changes on MRI in older adults with memory complaints and mild cognitive impairment: the AIBL Active trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Using genetics to enable studies on the prevention of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Cholinesterase inhibitors for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

The age-dependent relation of blood pressure to cognitive function and dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Current status of renin-aldosterone angiotensin system-targeting anti-hypertensive drugs as therapeutic options for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Calcium channel blockers and Alzheimer's disease: potential relevance in treatment strategies of metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

The role of estrogen in the treatment and prevention of dementia: introduction.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

The potential use of hormone-based therapeutics for the treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Estrogen therapy and Alzheimer's dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Estrogen therapy: is time of initiation critical for neuroprotection?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Extended results of the Alzheimer's disease anti-inflammatory prevention trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

The nitric oxide-scavenging properties of Ginkgo biloba extract EGb 761.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Cardioprotective and anti-oxidant effects of the terpenoid constituents of Ginkgo biloba extract (EGb 761).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Risk of dementia in diabetes mellitus: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Molecular links between Alzheimer's disease and diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Alzheimer's disease and diabetes: an integrative view of the role of mitochondria, oxidative stress, and insulin

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Therapeutic potential of statins in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Oxidative alterations in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

A randomized controlled Alzheimer's disease prevention trial's evolution into an exposure trial: the PREADViSE Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Nutrition in brain development and aging: role of essential fatty acids

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Flavonoids, cognition, and dementia: actions, mechanisms, and potential therapeutic utility for Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Vitamin D deficiency, cognitive impairment and dementia: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

1α,25-Dihydroxyvitamin D3 reduces cerebral amyloid-β accumulation and improves cognition in mouse models of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Cognitive reserve: implications for diagnosis and prevention of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Long-term effects of cognitive training on everyday functional outcomes in older adults

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Exercise, brain, and cognition across the life span

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Neuroprotective effects of physical activity on the brain: a closer look at trophic factor signaling

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Physical activity, diet, and risk of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Regulatory innovation and drug development for early-stage Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Prevention trials in Alzheimer's disease: an EU-US task force report.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

CERAD practice effects and attrition bias in a dementia prevention trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

The preclinical Alzheimer cognitive composite: measuring amyloid-related decline

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Mild cognitive impairment: ten years later

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Biomarkers for Alzheimer's disease therapeutic trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Understanding biomarkers of neurodegeneration: Novel approaches to detecting tau pathology.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Chronic disease long-term drug prevention trials: lessons from the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Design considerations in long-term intervention studies for the prevention of cognitive decline or dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Simulating effects of biomarker enrichment on Alzheimer's disease prevention trials: conceptual framework and example

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

An omnibus test for several hazard alternatives in prevention randomized controlled clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

How should we deal with missing data in clinical trials involving Alzheimer's disease patients?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Charting a path toward combination therapy for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

The Alzheimer's disease neuroimaging initiative: progress report and future plans

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

The European Dementia Prevention Initiative

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Dementia prevention: current epidemiological evidence and future perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Designing a large prevention trial: statistical issues.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

A randomized controlled trial investigating the effect of Pycnogenol and Bacopa CDRI08 herbal medicines on cognitive, cardiovascular, and biochemical functioning in cognitively healthy elderly people: the Australian Research Council Longevity Interv

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

A randomised controlled trial of aerobic exercise after transient ischaemic attack or minor stroke to prevent cognitive decline: the MoveIT study protocol

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Rationale and design of a double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of nimodipine in preventing cognitive impairment in ischemic cerebrovascular events (NICE)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

Preventing cognitive decline in older African Americans with mild cognitive impairment: design and methods of a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900153-2

7 January 2021

10.1016/S1474-4422(15)00153-2

Identifiers

DOI

1 reference

4 September 2017

1 reference

PubMed ID

26213339